Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders

Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders

Abstract Background Neuromyelitis optica spectrum disorders (NMOSD) are demyelinating autoimmune diseases in the central nervous system (CNS) that are characterized by a high relapse rate and the presence of anti-aquaporin 4 antibodies (AQP4-IgG) in the serum. Azathioprine (AZA) is a first-line immu...

Full description

Bibliographic Details
Main Authors:	Xindi Li, Shenghui Mei, Xiaoqing Gong, Heng Zhou, Li Yang, Anna Zhou, Yonghong Liu, Xingang Li, Zhigang Zhao, Xinghu Zhang
Format:	Article
Language:	English
Published:	BMC 2017-07-01
Series:	BMC Neurology
Subjects:	Neuromyelitis optica spectrum disorders (NMOSD) Azathioprine (AZA) Thiopurine S-methyltransferase (TPMT) 6-thioguanine nucleotides (6-TGNs) 6-methylmercaptopurine nucleotides (6-MMPNs)
Online Access:	http://link.springer.com/article/10.1186/s12883-017-0903-5

Similar Items

LC–MS/MS Method for Measurement of Thiopurine Nucleotides (TN) in Erythrocytes and Association of TN Concentrations With TPMT Enzyme Activity
by: Amol O. Bajaj, et al.
Published: (2022-03-01)

Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response
by: Abaji R, et al.
Published: (2017-05-01)

Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol
by: Linea Natalie Toksvang, et al.
Published: (2022-05-01)

Azathioprine‐induced pancytopenia: A case report
by: Keshav Raj Sigdel, et al.
Published: (2022-09-01)

Thiopurine S-Methyltransferase Polymorphism in Iraqi Paediatric Patients with Acute Lymphoblastic Leukaemia
by: NAWARS MOHAMMED, et al.
Published: (2019-01-01)

gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
by: Katsuyoshi Matsuoka
Published: (2020-07-01)

Monitoração terapêutica da azatioprina: uma revisão Therapeutic drug monitoring of azathioprine: a review
by: Maurílio Pacheco Neto, et al.
Published: (2008-06-01)

A drug‐repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6‐thioguanine as an effective therapeutic agent for TPMT‐low cancer cells
by: Inki Kim, et al.
Published: (2018-09-01)

Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease
by: Oliwia Zakerska-Banaszak, et al.
Published: (2022-03-01)

The role of polymorphisms of thiopurine methyltransferase in therapy with Azathioprine: preliminary study
by: Francesca Mortillaro, et al.
Published: (2018-11-01)

Usefulness and difficulties with the thiopurine pharmacogenomic NUDT15 genotyping test: Analysis of real-world data in Japan
by: Yoichi Kakuta, et al.
Published: (2023-11-01)

Use of thiopurines in inflammatory bowel disease: an update
by: Arshdeep Singh, et al.
Published: (2022-01-01)

Relapsing neuromyelitis optica spectrum disorder
by: M Lakshmi Lavanya, et al.
Published: (2021-01-01)

Thiopurine S-Methyltransferase Polymorphisms Predict Hepatotoxicity in Azathioprine-Treated Patients with Autoimmune Diseases
by: Heh-Shiang Sheu, et al.
Published: (2022-08-01)

Preemptive <i>TPMT</i> Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases
by: Sarahí Valdez-Acosta, et al.
Published: (2023-07-01)

Population-Specific Distribution of TPMT Deficiency Variants and Ancestry Proportions in Ecuadorian Ethnic Groups: Towards Personalized Medicine
by: Gallardo-Cóndor J, et al.
Published: (2023-11-01)

Correlation of thiopurine methyltransferase and inosine triphosphate pyrophosphatase polymorphisms and adverse effects induced by azathioprine treatment in Taiwanese dermatology patients
by: Ting-Shun Wang, et al.
Published: (2014-03-01)

Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation
by: Xando Díaz-Villamarín, et al.
Published: (2023-12-01)

Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis
by: Sanjeev Kharel, et al.
Published: (2021-11-01)

The Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review
by: Aline C. Ribeiro, et al.
Published: (2023-10-01)

Detection of Thiopurine S-Methyltransferase (TPMT) Polymorphisms TPMT*3A, TPMT*3B and TPMT*3C in Children with Acute Lymphoblastic Leukemia
by: Nawar S. Mohammed, et al.
Published: (2018-12-01)

Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?
by: Raphael P. Luber, et al.
Published: (2019-11-01)

Neuromyelitis Optica Spectrum Disorders (NMOSD); Diagnostic criteria (ORP-56)
by: Maryam Poursadeghfard
Published: (2023-01-01)

Case Report: Azathioprine: An Old and Wronged Immunosuppressant
by: Pedro R. Chocair, et al.
Published: (2022-06-01)

Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report
by: Takashi Yoshida, et al.
Published: (2023-12-01)

Improved HPLC Quantification of 6-Mercaptopurine Metabolites in Red Blood Cells: Monitoring Data and Literature Analysis
by: Tiphaine Adam de Beaumais, et al.
Published: (2022-10-01)

Detection of Hypoxanthine from Inosine and Unusual Hydrolysis of Immunosuppressive Drug Azathioprine through the Formation of a Diruthenium(III) System
by: Marta Orts-Arroyo, et al.
Published: (2021-01-01)

Association Between Genetic Polymorphisms of Metabolic Enzymes and Azathioprine-Induced Myelosuppression in 1,419 Chinese Patients: A Retrospective Study
by: Zhao-Yang Chen, et al.
Published: (2021-05-01)

Emerging trends and research foci of neuromyelitis optica spectrum disorder: a 20-year bibliometric analysis
by: Yue Su, et al.
Published: (2023-06-01)

A Practical Non-Extraction Direct Liquid Chromatography Method for Determination of Thiopurine S-Methyltransferase Activity in Inflammatory Bowel Disease
by: Fariborz Bahrehmand, et al.
Published: (2017-08-01)

6-Thioguanine Inhibits Herpes Simplex Virus 1 Infection of Eyes
by: Deyan Chen, et al.
Published: (2021-12-01)

Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency
by: Debbie S. Deben, et al.
Published: (2023-10-01)

DNA methylation of the TPMT gene and azathioprine pharmacokinetics in children with very early onset inflammatory bowel disease
by: Davide Selvestrel, et al.
Published: (2023-01-01)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
by: Jyh Yung Hor, et al.
Published: (2020-06-01)

TPMT and NUDT15 testing for thiopurine therapy: A major tertiary hospital experience and lessons learned
by: Liuh Ling Goh, et al.
Published: (2022-09-01)

Interleukin 6: at the interface of human health and disease
by: Elena Grebenciucova, et al.
Published: (2023-09-01)

Correlation between serum AQP-4 antibody, inflammatory cytokines and recurrence of neuromyelitis optica in patients with chronic insomnia
by: WANG Feng, et al.
Published: (2022-12-01)

Pharmacogenetic testing in oncology: a Brazilian perspective
by: Guilherme Suarez-Kurtz
Published: (2018-10-01)

Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder
by: Byung Soo Kong, et al.
Published: (2017-09-01)

MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis
by: Laura Clarke, et al.
Published: (2021-09-01)